Abstract:Obesity increases the incidence and progression of colon cancer. The chronic low-grade inflammation that often accompanies obesity is purported to promote these adverse outcomes. In obesity, remodeling of visceral white adipose tissue contributes to an inflammatory state via increased immune cell recruitment and production of proinflammatory cytokines. The aim of this study in a mouse model of obesity and colon carcinogenesis was to compare the effects of weight loss versus treatment with a nonsteroidal anti-inflammatory drug (sulindac) on tumor development and adipose and tumoral transcriptional changes. Azoxymethane (10 mg/kg) was intraperitoneally injected weekly into FVB/N male mice for 5 weeks to induce colon tumors. Mice were then randomized to an ad libitum 10 kcal% fat diet (control, n=20) or 60 kcal% fat diet to promote diet-induced obesity (DIO, n=55). After 15 weeks, DIO mice were randomized again to receive for an additional 7 weeks either: a) DIO diet (n=18); b) DIO diet supplemented with 140ppm sulindac (DIO+Su, n=19), or c) 10 kcal% fat control diet to generate formerly obese (FOb-LFD) mice (n=18). Mesenteric fat and colon tumors were collected for an Affymetrix Clariom D mouse gene expression microarray (n=5-6/group). FOb-LFD mice, but not DIO+Su mice, lost significant body weight and body fat. Relative to DIO mice, tumor burden and multiplicity were lower in control, DIO+Su, and FOb-LFD mice. Gene set enrichment analysis (GSEA) using the Hallmark gene sets revealed strikingly concordant transcriptional changes in the control, DIO+Su, and FOb-LFD mesenteric fat depots compared with DIO mice. Of the 8 immune related gene sets, 7 were uniformly suppressed (Normalized enrichment score (NES) >1.66, FDR q 1.45, FDR q<0.05), and none were suppressed in control, DIO+Su, and FOb+LFD tumors. Tumor transcriptional changes were less coherent with EPITHELIAL_MESENCHYMAL_TRANSITION and COAGULATION being the only gene sets commonly suppressed across all groups relative to DIO. A leading-edge analysis revealed that Lum, Pthlh, Sfrp4, Mmp8, and Serpine1 were commonly suppressed amongst tumors from groups other than DIO mice. Both weight loss and sulindac impeded the effects of chronic obesity on colon tumorigenesis. GSEA analyses of immune related gene sets indicated that weight loss and sulindac effectively suppressed inflammation in the adipose tissue but not in the tumor. The conserved immunological and metabolic transcriptional programs in the adipose tissue relative to the tumor suggests the possibility that paracrine signaling from the adipose to the tumor may underpin the observed beneficial effects of these interventions on obesity-driven colon tumor growth. Citation Format: Elaine M. Glenny, Laura W. Bowers, Michael F. Coleman, Jatin Roper, Stephen D. Hursting. Resolution of obesity-driven proinflammatory adipose signaling by weight loss or an NSAID is associated with reduced tumor burden in a mouse model of colon cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 14.

Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling

High-Fat Diet Propelled AOM/DSS-Induced Colitis-Associated Colon Cancer Alleviated by Administration of Aster glehni via STAT3 Signaling Pathway

Oroxylin A Inhibits Colitis-associated Carcinogenesis Through Modulating the IL-6/STAT3 Signaling Pathway

Ginsenoside Rk3 Ameliorates Obesity-Induced Colitis by Regulating of Intestinal Flora and the TLR4/NF-κB Signaling Pathway in C57BL/6 Mice

Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo

[Anemoside B4 regulates fatty acid metabolism reprogramming in mice with colitis-associated cancer]

Astragaloside IV inhibits AOM/DSS-induced colitis-associated tumorigenesis via activation of PPARγ signaling in mice

Abstract 14: Resolution of obesity-driven proinflammatory adipose signaling by weight loss or an NSAID is associated with reduced tumor burden in a mouse model of colon cancer

Toll-like receptor 3 signaling attenuated colitis-associated cancer development in mice

P083 the Protective Role of Vitamin D3 on Colitis-Associated Colorectal Cancer in a Mouse Model

Probiotic OMNi-BiOTiC® 10 AAD Reduces Cyclophosphamide-Induced Inflammation and Adipose Tissue Wasting in Mice

Consumption of the Total Western Diet Promotes Colitis and Inflammation-Associated Colorectal Cancer in Mice

Ginsenoside Rk3 Ameliorates Obesity-Induced Colitis by Modulating Lipid Metabolism in C57BL/6 Mice

A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy

Oroxylin A Inhibits Colitis by Inactivating NLRP3 Inflammasome.

Obesity Promotes Marrow-Derived Myeloid Cell Accumulation while Exercise Reduces Proliferative Signaling in Colon Cancer

Curcumin Attenuates Dextran Sodium Sulfate Induced Colitis in Obese Mice

Lactobacillus bulgaricus inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model

Tocotrienol suppresses colitis-associated cancer progression through TLR4 signaling in a mouse model of colorectal cancer

β-hydroxybutyrate Restrains Colitis-Associated Tumorigenesis by Inhibiting HIF-1α-Mediated Angiogenesis